MedTrace Logo

Monthly Injectable BUP for MA Use Disorder (MURB) Trial

NCT05283304 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-03-21

Study results available
· View outcomes & findings →

Summary

This study is a 12-week randomized, double-blind, placebo-controlled trial that will investigate the use of injectable buprenorphine (BUP-Inj) compared to injectable placebo (PBO-Inj) for the treatment of methamphetamine use disorder (MUD) among individuals with mild co-use of opioids.

Conditions

  • Methamphetamine-dependence

Interventions

DRUG

Buprenorphine injection (BUP-Inj)

Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)

OTHER

Placebo injection

Sublingual buprenorphine induction, then Placebo injectable (300 mg)

Sponsors & Collaborators

  • Madhukar H. Trivedi, MD

    lead OTHER

Principal Investigators

  • Madhukar Trivedi, MD · UT Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-24
Primary Completion
2023-10-20
Completion
2023-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05283304 on ClinicalTrials.gov